CAJ | 학술논문

目的：研究尤瑞克林联合巴曲酶治疗进展性脑梗死的疗效及安全性。方法进展性脑梗死患者96例，按随机数字表随机分为两组，每组48例。对照组除常规治疗外，隔日应用1次巴曲酶（10 U、5 U、5 U），治疗组在对照组基础上应用尤瑞克林0.15 PNA 单位加入生理盐水100 ml 静脉滴注（约40滴/ min），连用14 d。观察治疗前及用药7 d、14 d 及28 d 后神经功能缺损（NIHSS 评分）及实验室指标变化。结果治疗组和对照组比较总有效率显著提高（P <0.05），治疗前后两组均无明显的不良反应。结论尤瑞克林联合巴曲酶治疗进展性脑梗死安全有效，值得临床推广。
목적：연구우서극림연합파곡매치료진전성뇌경사적료효급안전성。방법진전성뇌경사환자96례，안수궤수자표수궤분위량조，매조48례。대조조제상규치료외，격일응용1차파곡매（10 U、5 U、5 U），치료조재대조조기출상응용우서극림0.15 PNA 단위가입생리염수100 ml 정맥적주（약40적/ min），련용14 d。관찰치료전급용약7 d、14 d 급28 d 후신경공능결손（NIHSS 평분）급실험실지표변화。결과치료조화대조조비교총유효솔현저제고（P <0.05），치료전후량조균무명현적불량반응。결론우서극림연합파곡매치료진전성뇌경사안전유효，치득림상추엄。
Objective To study the effects and adverse reactions of urinary kallidinogenase (UK)combined with batroxobin on acute cerebral infarction. Methods The 96 patients with acute cer-ebral infarction were randomly divided into urinary kallidinogenase group and control group,with 48 pa-tients in each group. The patients in control group were given conventional treatment and batroxobin (10U,5U)every two days,and the patients in treatment group were additionly given UK(0. 15 PNA) added to saline solution 100 ml for intravenous drip,for 14 days. Effects were judged according to the National Institutes of Health stroke scale(NIHSS). Changes of neural function were studied. Results The total effective rate of urinary kallidinogenase group was 89. 58% . The total effective rate of control group was 77. 08%. The total effective rate of urinary kallidinogenase group was significantly higher than that of control group after 14 days of treatment. There was significant difference between the two groups (P < 0. 05). There were no adverse reactions in the two groups. Conclusions Urinary kallidinogenase combined with batroxobin is effective and safe in treatment of the patients with acute cerebral infarction, so it is worthy to be popularized in clinics.